| 24.04 22:07 | dpa-AFX: Biomarin Pharmaceutical Inc. Q1 Profit Increases, beats estimates |
| 24.04 22:05 | dpa-AFX: *BIOMARIN Q1 NET INCOME $88.7 MLN VS. $50.9 MLN PRIOR YEAR |
| 24.04 22:05 | dpa-AFX: *BIOMARIN Q1 EPS $0.46 VS .$0.27 YEAR AGO |
| 24.04 22:05 | dpa-AFX: *BIOMARIN Q1 REVENUES $648.8 MLN VS. $596.4 MLN LAST YEAR |
| 24.04 21:03 | dpa-AFX: Biomarin Pharma Q1 24 Earnings Conference Call At 4:30 PM ET |
| 22.02 22:06 | dpa-AFX: Biomarin Pharmaceutical Inc. Q4 Earnings Summary |
| 22.02 22:06 | dpa-AFX: *BIOMARIN Q4 EPS $0.11 VS. BREAKEVEN YEAR AGO |
| 22.02 22:06 | dpa-AFX: *BIOMARIN Q4 REVENUES $646.2 MLN VS. $537.5 MLN LAST YEAR |
| 22.02 22:06 | dpa-AFX: *BIOMARIN Q4 NET INCOME $20.4 MLN VS. LOSS $249K PRIOR YEAR |
| 22.02 12:03 | dpa-AFX: Biomarin Pharmaceutical Q4 23 Earnings Conference Call At 4:30 PM ET |
| 06.02 14:32 | dpa-AFX: *BIOMARIN TO PRESENT ROCTAVIAN DATA HIGHLIGHTING LONG-TERM DURABILITY AT EAHAD CONGRESS |
| 20.12 22:08 | dpa-AFX: *BIOMARIN ANNOUNCES GOVERNANCE ENHANCEMENTS AND VALUE CREATION INITIATIVES |
| 28.11 14:49 | dpa-AFX: BioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In Germany |
| 28.11 14:34 | dpa-AFX: *BIOMARIN REPORTS DEAL WITH GERMAN HEALTH INSURANCE FUND ON REIMBURSEMENT AMOUNT FOR ROCTAVIAN FOR SEVERE HEMOPHILIA A |
| 01.11 21:16 | dpa-AFX: Biomarin Pharmaceutical Inc. Q3 Earnings Summary |
| 01.11 21:13 | dpa-AFX: *BIOMARIN Q3 REVENUES $581.3 MLN VS. $505.3 MLN LAST YEAR |
| 01.11 21:12 | dpa-AFX: *BIOMARIN Q3 EPS $0.21 VS. LOSS $0.04 YEAR AGO |
| 01.11 21:09 | dpa-AFX: *BIOMARIN APPOINTS ALEXANDER HARDY AS PRESIDENT AND CEO |
| 01.11 20:00 | dpa-AFX: Biomarin Pharmaceutical Q3 23 Earnings Conference Call At 4:30 PM ET |
| 30.10 07:28 | dpa-AFX: *JPMORGAN NIMMT BIOMARIN PHARMA MIT 'OVERWEIGHT' WIEDER AUF - ZIEL 111 USD |
|
|
